Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Lymphomas, Diseases, aggressive lymphoma, Lymphoid Malignancies
Methods: In this study, a total of 815 patients diagnosed with DLBCL and treated with R-CHOP or R-CHOP-like regimens over a five-year period were reviewed. The authors conducted clinical, immunohistochemical, and genetic analyses, with a specific focus on cyclin D1. Immunohistochemistry was used to identify cyclin D1-positive patients, and fluorescence in situ hybridization was employed to assess cyclin D1 gene (CCND1) rearrangements. A comparison was made between DLBCL patients with and without cyclin D1 expression in terms of clinical, immunohistochemical, and genetic features.
Results: Among the DLBCL patients, 16 individuals (2.61%) exhibited cyclin D1 expression without CCND1 gene rearrangements. Cyclin D1-positive DLBCLs were observed in patients with a median age of 58.88 ± 4.07 years, with 93.75% of them classified as stage IV. The majority of cyclin D1-positive patients (81.25%) displayed elevated serum lactate dehydrogenase (LDH) levels and advanced international prognostic index (IPI) scores. Additionally, all cases exhibited a proliferation rate exceeding 80%, and a significant proportion (93.75%) demonstrated MYC expression. Cyclin D1-positive DLBCLs were associated with elevated LDH levels, higher IPI scores, advanced stage, increased Ki-67 proliferation, and MYC expression (p<0.05). However, no significant differences were observed in other clinical characteristics and immunohistochemical features. Patients with cyclin D1 expression experienced shorter progression-free survival (PFS) and overall survival (OS) compared to cyclin D1-negative patients (p<0.05). Next-generation sequencing (NGS) was performed to explore the molecular mechanisms underlying cyclin D1-positive DLBCL. Among the top 50 gene alterations identified, all samples exhibited BRD9 and NOTCH2NL gene mutations, while gene alterations in the PI3K/AKT signaling pathways were evident in cyclin D1-positive DLBCLs. Furthermore, a more pronounced variation in the MTOR gene was observed between cyclin D1-positive and negative patients. Notably, DLBCL patients with cyclin D1 expression frequently exhibited CDKN2A and CDKN2B gene deletions, known to regulate the cell cycle transition from G1 to S phase in tumors.
Conclusion: Cyclin D1-positive DLBCL patients exhibited aggressive clinical behavior and inferior survival outcomes compared to DLBCL patients without cyclin D1 expression. NGS studies revealed a potential association between cyclin D1 expression and abnormal cell cycle transition and AKT pathway activation. These findings support the existence of a diagnostically challenging "gray zone" of DLBCL associated with cyclin D1 expression.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts